Use of Nanomaterials for Diagnosis and Treatment: The Advancement of Next-Generation Antiviral Therapy

Nature-inspired innovations: unlocking the potential of biomimicry in bionanotechnology and beyond

Bionanotechnology research has surged to the forefront of scientific innovation, propelling the exploration of cutting-edge technologies and interdisciplinary collaboration. Biomimicry, which harnesses nature's ingenuity, drives the development of novel research-based solutions in diverse fields such as vaccines, medicine, and biomedical devices. Nature's role is becoming increasingly pivotal in addressing complex challenges related to environmental conservation, human health, and pandemic preparedness, including those posed by SARS-CoV-2 and other emerging pathogens. Progress in this domain encompasses understanding nature´s mechanisms to develop advanced materials inspired by biological structures. Biomimetic innovations have the potential to revolutionize industries, reduce environmental impacts, and facilitate a more harmonious relationship between humans and nature while considering bioethics, underlining the necessity of conducting responsible research and implementing biomimetic advancements conscientiously. As biomimicry continues to grow, integrating ethical guidelines and policies will ensure these nature-inspired technologies' sustainable development and application, ultimately contributing to a more resilient and adaptive society. This mini-review article broadly overviews bionanotechnology applications based on natural examples.

Viral nanoparticles: Current advances in design and development

Viral nanoparticles (VNPs) are self-assembling, adaptable delivery systems for vaccines and other therapeutic agents used in a variety of biomedical applications. The potential of viruses to invade and infect various hosts and cells renders them suitable as potential nanocarriers, possessing distinct functional characteristics, immunogenic properties, and improved biocompatibility and biodegradability. VNPs are frequently produced through precise genetic or chemical engineering, which involves adding diverse sequences or functional payloads to the capsid protein (CP). Several spherical and helical plant viruses, bacteriophages, and animal viruses are currently being used as VNPs, or non-infectious virus-like particles (VLPs). In addition to their broad use in cancer therapy, vaccine technology, diagnostics, and molecular imaging, VNPs have made important strides in the realms of tissue engineering, biosensing, and antimicrobial prophylaxis. They are also being used in energy storage cells due to their binding and piezoelectric properties. The large-scale production of VNPs for research, preclinical testing, and clinical use is fraught with difficulties, such as those relating to cost-effectiveness, scalability, and purity. Consequently, many plants- and microorganism-based platforms are being developed, and newer viruses are being explored. The goal of the current review is to provide an overview of these advances.